Pen­ny stock forges ahead with an NDA for Duchenne treat­ment, seek­ing pri­or­i­ty re­view

Af­ter set­backs and de­lays, the Swiss biotech San­thera is look­ing to have its treat­ment for Duchenne mus­cu­lar dy­s­tro­phy get past the FDA.

San­thera, along with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER